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Is it the Operator or the Operation That Matters?Michel R. Le May, MD, Kuljit Singh, MD, George A. Wells, PHDABSTRACTFro
sh
MaIn the recently published MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic
Implementation of angioX) trial, the use of transradial access (TRA) compared to transfemoral access (TFA) during
percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) was associated with a reduction in net
adverse cardiovascular events. However, the results of MATRIX must be interpreted with caution due to several limita-
tions including the strong modulating effect of operator/center experience on the relative efﬁcacy of TRA and the in-
clusion of 2 distinct patient populations (ST-segment elevation and non-ST-segment elevation ACS). Therefore, although
important, the results of MATRIX have strong limitations and are not sufﬁcient to deﬁnitively identify an approach of
choice during PCI for ACS. Further research is needed before strong, evidence-based recommendations regarding the
approach of choice during PCI for ACS can be made. (J Am Coll Cardiol Intv 2015;8:1405–9) © 2015 by the American
College of Cardiology Foundation.A recently published, large, randomized study,MATRIX (Minimizing Adverse HaemorrhagicEvents by TRansradial Access Site and Sys-
temic Implementation of angioX) (1), compared
transradial access (TRA) to transfemoral access
(TFA) in patients presenting with acute coronary
syndromes (ACS) who were referred for percuta-
neous coronary intervention (PCI). The results of
this trial have been interpreted to suggest that TRA
is superior to TFA in reducing net adverse clinical
events (NACE) through a reduction of bleeding and
mortality. This conclusion could signiﬁcantly affect
our practice guidelines and lead to a strong recom-
mendation that the approach of choice for PCI in
ACS is radial rather than femoral. Hence, this trial
has signiﬁcant implications for both PCI centers
and interventionalists, and it could have an effect
on medical practice and education. However, the
MATRIX trial has serious shortcomings that need to
be considered.m the University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Th
ips relevant to the contents of this paper to disclose.
nuscript received June 19, 2015; accepted June 23, 2015.The MATRIX trial randomly assigned 8,404 ACS
patients to TRA (n ¼ 4,197) or TFA (n ¼ 4,207) to
compare clinical outcomes in patients referred for
coronary angiography and PCI (1). The study was
designed with 2 30-day coprimary endpoints: 1) major
adverse cardiovascular events (MACE), deﬁned as
all-cause mortality, myocardial infarction, or stroke;
and 2) NACE, deﬁned as major bleeding unrelated to
coronary artery bypass graft surgery or major adverse
cardiovascular events. Major bleeding was classiﬁed
according to the Bleeding Academic Research Con-
sortium (2). Because of multiple comparisons, the
2-sided a was pre-speciﬁed at 0.025 for each primary
endpoint. MACE was recorded in 8.8% of patients
assigned to TRA and in 10.3% of patients assigned to
TFA (p ¼ 0.03); this was interpreted as nonsigniﬁcant.
However, the rate of NACE was signiﬁcantly lower in
patients assigned to TRA compared to TFA (9.7% vs.
11.7%, respectively; p ¼ 0.009); a difference said to be
driven by major bleeding (1.6% vs. 2.3%; p ¼ 0.013)e authors have reported that they have no relation-
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndromes(s)
MACE = major adverse
cardiovascular events(s)





PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TFA = transfemoral access
TRA = transradial access
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1406and all-cause mortality (1.6% vs. 2.2%; p ¼
0.045). The authors suggest that the beneﬁts
associated with implementation of TRA for
the treatment of ACS “might be especially
relevant for countries such as the USA where
use of the radial approach is currently un-
common” (3). However, a critical appraisal of
the MATRIX trial’s results will cast a word
of caution before accepting the authors’
conclusions.
First, it is quite clear that the outcomes
were dependent upon the center’s experi-
ence at performing PCI. A center’s experience
is determined by its access preference (i.e.,
the proportion of TRA vs. TFA) and by its
annual PCI volume; in addition, the experi-
ence levels of the operator, the catheteriza-tion team, as well as the team monitoring the patient
after the PCI all contribute to the overall experience
of the center. The MATRIX study divided patients
into 3 groups based on the participating center’s
proportion of radial PCIs: “low” (14.9% to 64.4%),
intermediate (65.4% to 79.0%), and high (80.0% to
98.0%). The results of this stratiﬁed analysis are
shown in Figure 1. As noted by the authors, and
illustrated in the ﬁgure, there is a strong interaction
between the randomized mode of access and the
center’s proportion of radial procedures for both
MACE (p ¼ 0.0048) and NACE (p ¼ 0.0048). This
interaction is so strong that to compare TRA and TFA
without taking the center’s experience into consid-
eration would be an oversight.
In fact, the only time TRA is signiﬁcantly better
than TFA occurs when the results are considered only
for centers with a high proportion (80.0% to 98.0%)
of PCIs done using TRA. There is no difference even
when the proportion of TRA is as high as 79% (14.9%
to 79.0%). Although the labels “low,” “intermediate,”
and “high” are used, more appropriate labels would
be “intermediate,” “high,” and “very high,” respec-
tively, given the percentages that they represent. It is
only in the “very high” group that there is a differ-
ence favoring TRA, and it occurs in centers with
essentially no or very limited TFA experience. One
could argue that operators in these centers have
optimal TRA skills that enable the beneﬁt of TRA to be
more evident; however, it remains unexplained why
the absolute rates of MACE and NACE in the TRA
group were unexpectedly higher in centers with a
“high” proportion of radial procedures compared
with those in the “low” and “intermediate” centers.
Furthermore, in the “high” radial proportion centers,
the rates of MACE and NACE in the TFA group were
excessive, 15.5% and 17.1%, respectively, comparedwith the rates reported for centers with a “low” or
“intermediate” proportion of radial procedures.
Notably, these results did not appear to be linked to
the overall annual PCI volume.
An alternative explanation is that centers perform-
ing PCI almost exclusively by TRA have limited
contemporary experience with TFA and consequently
have more complications. Randomizing patients to
receive TFA in centers with very little experience
would obviously be detrimental for outcomes in the
TFA group.With such an interaction, one needs to take
center experience into consideration either by inter-
preting the results within levels of center experience
or by statistically adjusting the results by including
center experience as a covariate in any modeling.
Hence, the analysis of this trial may have actually
assessed center experience rather than the use of the
access site itself, and this may very well account for
the measured differences in clinical outcomes.
Second, the MATRIX trial had a complex design
that attempted to resolve many questions by incor-
porating multiple comparisons: 1) TRA versus TFA; 2)
bivalirudin monotherapy versus unfractionated hep-
arin plus provisional glycoprotein platelet inhibitors
(GPIs); and 3) short- versus long-term administration
of bivalirudin. This approach likely introduced mul-
tiple interventions that could potentially distort the
interpretation of the results.
In light of the multiple comparisons, the alpha for
signiﬁcance was set at 0.025 for the 2 primary out-
comes (4). However, the p value was reset at 0.05 for
the individual components of MACE and NACE. One
could argue that, given the 4 components of NACE, a
Bonferroni-corrected alpha of 0.0125 should have
been used. This argument coincides with many
authors’ recommendations, most recently by Rauch
et al. (5), that strategies such as the Bonferroni-
Holm’s approach should be used when evaluating
the components of a composite outcome. In so doing,
the difference reported for mortality in the MATRIX
trial would not have been statistically signiﬁcant.
Third, the MATRIX trial enrolled patients present-
ing with ST-segment elevation myocardial infarction
(STEMI) and non–ST-segment elevation acute coro-
nary syndrome (NSTE-ACS). Of note, the MATRIX trial
did not stratify STEMI and NSTE-ACS in the
randomization process (4). Without including strati-
ﬁcation into the study design, one needs to exercise
caution in the interpretation of the results in these
subgroups as the 2 clinical entities differ considerably
in pathophysiology and management options, thus
possibly skewing the results. Notable differences
between both patient populations include: 1) the
acuity level; 2) the importance of time to reperfusion;
FIGURE 1 Difference in MACE and NACE Between TRA and TFA in the MATRIX Trial
Stratiﬁed by Center’s Proportion of Radial PCI
(A) Difference in major adverse cardiovascular events (MACE) between transradial (TRA)
and transfemoral (TFA) access in the MATRIX (Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic Implementation of angioX) trial, subdivided as per
each center’s proportion of radial access into low (14.9% to 64.4%), intermediate (65.4%
to 79.0%), and high (80.0% to 98.0%). MACE was deﬁned as all-cause mortality,
myocardial infarction, or stroke. (B) Difference in net clinical adverse events (NACE)
between TRA and TFA in the MATRIX trial, subdivided as per each center’s proportion of
radial access. NACE was deﬁned as major bleeding unrelated to coronary artery bypass
surgery or major adverse cardiovascular events. PCI ¼ percutaneous coronary intervention.
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14073) the choice and duration of anticoagulant therapy;
and 4) the likelihood of bleeding (6).
The MATRIX trial enrolled a total of 4,010 of 8,404
(47.7%) STEMI patients. A subgroup analysis of these
STEMI patients found no difference in MACE (121 of
2,001 [6.0%] in the TRA group vs. 126 of 2,009 [6.3%]
in the TFA group; p ¼ 0.77), and no difference in
NACE (142 of 2,001 [7.1%] in the TRA group vs. 165 of
2,009 [8.2%] in the TFA group, p ¼ 0.19).
Interestingly, a similar study, the RIVAL (RadIal Vs
femorAL access for coronary intervention) trial (7),
compared TRA with TFA in 7,021 patients presenting
with ACS, of which 1,958 presented with STEMI (8).
The primary outcome, like in the MATRIX trial, was
deﬁned as NACE, a composite of death, myocardial
infarction, stroke, or non-coronary artery bypass graft
surgery–related major bleeding within 30 days; the
primary outcome, NACE, was measured in 3.7% of
patients in the TRA group and in 4.0% of patients
in the TFA group (p ¼ 0.50). Hence, RIVAL was a
negative study. In addition, the RIVAL study showed
no signiﬁcant difference in mortality between TRA
and TFA and no signiﬁcant difference in reinfarction,
stroke, or major bleeding. Despite these negative re-
sults, the RIVAL study claimed a signiﬁcant reduction
in mortality in the subgroup of patients with STEMI
treated with TRA (1.3% vs. 3.2%; p ¼ 0.006) (8).
However, amongst NSTE-ACS patients, there was a
troublesome trend toward a higher mortality in the
TRA group (1.2% vs. 0.8%; p ¼ 0.08). With respect to
NACE, NSTE-ACS patients beneﬁtted less from TRA
than those with STEMI (interaction p ¼ 0.026); in
contrast, the MATRIX trial identiﬁed a trend indi-
cating that TRA beneﬁted NSTE-ACS patients (relative
risk: 0.84; 95% conﬁdence interval: 0.72 to 0.97)
rather than STEMI patients.
It remains unclear why differences in clinical out-
comes in STEMI and NSTE-ACS populations were
discordant between the 2 trials. Because many con-
founding factors could affect the results, it may not
be appropriate to include these 2 populations in a
single trial assessing the access site for PCI, unless
stratiﬁcation is included in the study design.
Fourth, MATRIX involved drugs such as GPIs,
which have been shown to increase bleeding and
mortality (9,10). In a pooled analysis of patients
enrolled in PCI randomized trials comparing bivalir-
udin to heparin plus GPIs, non–access site bleeding
represented two-thirds of all bleeding events and was
associated with a 4-fold increase in 1-year mortality;
access site bleeding represented one-third of the
bleeds and was associated with a 2-fold increase in
1-year mortality (11). Even if TRA could reduce most
access site bleeds, it would likely not reduce non–access site bleeds, which not only constitute a sig-
niﬁcant proportion of total bleeds but are associated
with a greater risk of mortality. Furthermore, an
important reduction in total bleeding events would
be expected if GPIs were avoided altogether.
Fifth, MATRIX did not report on the use of
vascular closure devices (VCDs). These devices have
been reported to reduce femoral bleeding. Amongst
12,937 patients undergoing angiography/PCI, VCDs
were associated with a nearly 50% propensity-
adjusted reduction in vascular complications (12).
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Intervention Triage Strategy) trial, the use of a VCD
(Angio-Seal, St. Jude Medical, St. Paul, Minnesota),
bivalirudin monotherapy, or both minimized rates of
major access site bleed, 2.5% in VCD versus 3.3% with
no VCD (relative risk: 0.76; 95% conﬁdence interval:
0.61 to 0.94); bleeding was lowest in patients tre-
ated with both bivalirudin monotherapy and a VCD
(0.7%) (13). In the RADIAMI II (Radial Versus Femoral
Approach for Percutaneous Coronary Interventions in
Patients With Acute Myocardial Infarction) trial, the
incidence of bleeding complications with primary PCI
were not signiﬁcantly different between TRA and
TFA plus a VCD (StarClose, Abbott Laboratories,
Abbott Park, Illinois) (14). Similarly, in the RIVAL
trial, 25.6% of patients assigned to TFA received a
VCD: bleeding was 0.7% with TRA and 0.7% with TFA
with a VCD (vs. 1% for TFA without a VCD) (7).
Furthermore, the use of VCD improves patient com-
fort by eliminating the need for a femoral clamp, and
has become standard practice in many centers.
Finally, cumulative radiation exposure is a
potential risk for the interventionalist and should
therefore be considered when evaluating the efﬁcacy
of both access sites. In the MATRIX study, radiation
exposure was not reported. In the RIVAL study,
TRA was associated with longer ﬂuoroscopy time:
9.8 min (5.8 to 15.0 min) vs. 8.0 min (4.5 to 13.0 min);
p < 0.0001 (7). This observation is of concern in view
of a recent report on excessive malignancies found in
the left cerebral hemisphere amongst intervention-
alists (15). This is an important secondary outcome
that should be of great interest to the interventional
community, which houses high-volume operators
who are progressively accommodating TRA as the
preferred choice. Cumulative small differences in ra-
diation exposure may become signiﬁcant throughout
the career of high-volume operators. Because inter-
ventional cardiologists have the highest radiation
exposure amongst health professionals, studies
“further delineating occupational risks are essential”
(15).
In summary, the conclusion reached by the authors
of the MATRIX trial, stating that TRA reduces net
adverse clinical outcomes as compared with TFA in
patients with ACS undergoing invasive assessment,
needs to be interpreted with caution. Although, theMATRIX trial was designed to resolve clinically rele-
vant questions, the trial had several shortcomings.
Primarily, the analyses of the results clearly demon-
strate that operator/center experience is a key vari-
able inﬂuencing the measured outcomes. Moreover,
the trial introduced too many confounders in an
attempt to resolve multiple questions. Thus,
the interpretation of the culminated results may be
distorted, given the multiple interactions and the
inclusion of 2 distinct patient populations. Finally,
the MATRIX trial did not apply pharmaceutical
strategies or report on the usage of vascular closing
devices that may reduce bleeding. The MATRIX trial
also did not report on cumulative radiation exposure,
which should be an important risk factor incorporated
into the efﬁcacy evaluation of both access sites.
A change in guidelines favoring TRA may not be
appropriate for all patients, institutions, and cardi-
ologists. It would be undesirable for skilled and
well-established interventionalists who have been
highly successful with TFA to change practice
without the results of a trial speciﬁcally designed to
resolve the debate. It would also be undesirable for
interventionalists who practice in lower-volume
centers to feel compelled to change practice based
on the current evidence as this may not beneﬁt
patients. Furthermore, in some clinical situations,
such as cardiogenic shock, proﬁciency at performing
PCI via the TFA could ensure better outcomes.
Therefore, it is important that interventional pro-
grams aim to ensure competency at performing the
2 approaches. Additional trials, particularly in the
STEMI population, are needed to resolve the debate
on access site looking at mortality as a primary
outcome and should be conducted in centers where
there is a reasonable balance in the centers’ experi-
ence at performing PCI via either access mode. From
these future trials, the question of whether it is the
“operator’s experience or the operation itself that
matters,” can ﬁnally be answered.
ACKNOWLEDGMENT The authors thank Christina
Osborne for her assistance in editing the manuscript.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Michel R. Le May, Ottawa Heart Institute, 40 Ruskin
Street, Ottawa, Ontario K1Y 4W7, Canada. E-mail:
mlemay@ottawaheart.ca.RE F E RENCE S1. Valgimigli M, Gagnor A, Calabro P, et al. Radial
versus femoral access in patients with acute cor-
onary syndromes undergoing invasive manage-
ment: a randomised multicentre trial. Lancet 2015;
385:2465–76.2. Mehran R, Rao SV, Bhatt DL, et al. Standardized
bleeding deﬁnitions for cardiovascular clinical
trials: a consensus report from the Bleeding Aca-
demic Research Consortium. Circulation 2011;123:
2736–47.3. Bradley SM, Rao SV, Curtis JP, et al. Change in
hospital-level use of transradial percutaneous coro-
nary intervention and periprocedural outcomes: in-
sights from theNational Cardiovascular Data Registry.
Circ Cardiovasc Qual Outcomes 2014;7:550–9.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5 Le May et al.
S E P T E M B E R 2 0 1 5 : 1 4 0 5 – 9 Radial Versus Femoral Access in ACS
14094. Valgimigli M. Design and rationale for the
Minimizing Adverse haemorrhagic events by
TRansradial access site and systemic Imple-
mentation of angioX program. Am Heart J 2014;
168:838–45.
5. Rauch G, Rauch B, Schuler S, Kieser M. Oppor-
tunities and challenges of clinical trials in cardi-
ology using composite primary endpoints. World J
Cardiol 2015;7:1–5.
6. Mehran R, Pocock SJ, Nikolsky E, et al. A risk
score to predict bleeding in patients with acute
coronary syndromes. J Am Coll Cardiol 2010;55:
2556–66.
7. Jolly SS, Yusuf S, Cairns J, et al. Radial versus
femoral access for coronary angiography and
intervention in patients with acute coronary syn-
dromes (RIVAL): a randomised, parallel group,
multicentre trial. Lancet 2011;377:1409–20.
8. Mehta SR, Jolly SS, Cairns J, et al. Effects of
Radial Versus Femoral Artery Access in Patients
With Acute Coronary Syndromes With or WithoutST-Segment Elevation. J Am Coll Cardiol 2012;60:
2490–9.
9. Stone GW, Witzenbichler B, Guagliumi G, et al.
Bivalirudin during primary PCI in acute myocardial
infarction. N Engl J Med 2008;358:2218–30.
10. Stone GW, Witzenbichler B, Guagliumi G, et al.
Heparin plus a glycoprotein IIb/IIIa inhibitor versus
bivalirudin monotherapy and paclitaxel-eluting
stents versus bare-metal stents in acute myocar-
dial infarction (HORIZONS-AMI): ﬁnal 3-year re-
sults from a multicentre, randomised controlled
trial. Lancet 2011;377:2193–204.
11. Verheugt FW, Steinhubl SR, Hamon M, et al.
Incidence, prognostic impact, and inﬂuence of
antithrombotic therapy on access and nonaccess
site bleeding in percutaneous coronary interven-
tion. J Am Coll Cardiol Intv 2011;4:191–7.
12. Arora N, Matheny ME, Sepke C, Resnic FS.
A propensity analysis of the risk of vascular com-
plications after cardiac catheterization procedures
with the use of vascular closure devices. Am Heart
J 2007;153:606–11.13. Sanborn TA, Ebrahimi R, Manoukian SV, et al.
Impact of femoral vascular closure devices and
antithrombotic therapy on access site bleeding in
acute coronary syndromes: The Acute Catheteri-
zation and Urgent Intervention Triage Strategy
(ACUITY) trial. Circ Cardiovasc Interv 2010;3:
57–62.
14. Chodor P, Kurek T, Kowalczuk A, et al. Radial
vs femoral approach with StarClose clip placement
for primary percutaneous coronary intervention in
patients with ST-elevation myocardial infarction.
RADIAMI II: a prospective, randomised, single
centre trial. Kardiol Pol 2011;69:763–71.
15. Roguin A, Goldstein J, Bar O. Brain tumours
among interventional cardiologists: a cause for
alarm? Report of four new cases from two cities
and a review of the literature. EuroIntervention
2012;7:1081–6.
KEY WORDS acute coronary syndrome(s),
femoral approach, percutaneous coronary
intervention, radial approach
